Two Point Capital Management Inc. Takes $7.28 Million Position in Stryker Corporation $SYK

Key Points

• Two Point Capital Management Inc. has acquired a new position in Stryker Corporation, purchasing 18,403 shares valued at approximately $7.28 million, making it the institutional investor's 15th largest holding.
• Insider activity shows Director Ronda E. Stryker sold 200,000 shares for about $75.29 million, representing a 5.84% decrease in her ownership of the company's stock.
• Analysts maintain an average consensus rating of "Moderate Buy" for Stryker Corporation, with target prices ranging from $415 to $445.

Two Point Capital Management Inc. bought a new position in Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 18,403 shares of the medical technology company's stock, valued at approximately $7,281,000. Stryker makes up about 3.1% of Two Point Capital Management Inc.'s portfolio, making the stock its 15th biggest holding.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company's stock worth $12,306,572,000 after purchasing an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company's stock worth $4,515,847,000 after buying an additional 1,021,496 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company's stock worth $838,640,000 after buying an additional 261,058 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Stryker by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company's stock worth $776,871,000 after buying an additional 83,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Stryker by 1.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company's stock valued at $750,223,000 after acquiring an additional 30,329 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SYK shares. Rothschild & Co Redburn assumed coverage on Stryker in a research report on Thursday, September 18th. They set a "neutral" rating and a $420.00 target price for the company. Truist Financial set a $415.00 target price on shares of Stryker and gave the stock a "hold" rating in a report on Monday, August 4th. Wells Fargo & Company upped their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. BTIG Research reiterated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Finally, Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. Fourteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $430.33.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Stock Performance

Shares of NYSE:SYK opened at $366.50 on Friday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The stock has a market capitalization of $140.12 billion, a P/E ratio of 48.54, a PEG ratio of 2.62 and a beta of 0.94. The firm has a fifty day simple moving average of $383.47 and a two-hundred day simple moving average of $378.96. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. During the same period in the prior year, the company earned $2.81 EPS. The business's revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is currently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.